Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 86

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 86
---
and other factors. These restrictions and requirements for payment may impair our ability to sell, license or otherwise transfer our
technology assets outside of Israel or to outsource or transfer development or manufacturing activities with respect to any product or
technology outside of Israel. Furthermore, the consideration available to our shareholders in a transaction involving the transfer outside
of Israel of technology or know-how developed with IIA funding (such as a merger or similar transaction) may be reduced by any amounts
that we are required to pay to the IIA. The terms and conditions of the IIA grants may require that a company which ceases the development
of know-how, technology or products using IIA grants not due to a failure of such development activities, be required to repay such amount
of grants, which in our case, amount to $2.6 million (including interest at the amount of $0.3 million).

We may not be able to enforce covenants not-to-compete under current Israeli law that might result in added competition for our products.

We have non-competition agreements
with all of our employees, all of which are governed by Israeli law. These agreements prohibit our employees from competing with or working
for our competitors, generally during their employment and for up to 12 months after termination of their employment. However, Israeli
courts are reluctant to enforce non-compete undertakings of former employees and tend, if at all, to enforce those provisions for relatively
brief periods of time in restricted geographical areas, and only when the employee has obtained unique value to the employer specific
to that employer’s business and not just regarding the professional development of the employee. If we are not able to enforce
non-compete covenants, we may be faced with added competition.

Provisions of Israeli law may delay, prevent or otherwise impede a merger with, or an acquisition of, us, which could prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders.

Israeli
corporate law regulates mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals
for transactions involving directors, officers or significant shareholders and regulates other matters that may be relevant to such types
of transactions. For example, a merger may not be consummated unless at least 50 days have passed from the date on which a merger
proposal is filed by each merging company with the Israel Registrar of Companies and at least 30 days have passed from the date
on which the shareholders of both